Analyst Price Targets — OBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 11, 2026 10:57 am | Matt O'Brien | Piper Sandler | $10.00 | $4.46 | TheFly | Orchestra BioMed price target raised to $10 from $9 at Piper Sandler |
| May 13, 2026 9:14 am | Matt Miksic | Barclays | $13.00 | $4.06 | TheFly | Orchestra BioMed price target raised to $13 from $12 at Barclays |
| January 9, 2026 12:21 pm | Matt Miksic | Barclays | $12.00 | $4.84 | TheFly | Orchestra BioMed price target raised to $12 from $11 at Barclays |
| March 20, 2025 9:42 am | Marie Thibault | BTIG | $12.00 | $4.35 | TheFly | Orchestra BioMed initiated with a Buy at BTIG |
Latest News for OBIO
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on September 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock…
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C.
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Thursday, Sept. 10, 2026 at 1:30pm ET and will also…
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.5 per share a year ago.
Affinity Asset Advisors LLC lessened its holdings in shares of Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) by 29.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 402,550 shares of the company's stock after selling 170,254 shares during the quarter. Affinity Asset Advisors
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OBIO.
U.S. House Trading
No House trades found for OBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.